Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01569750 · ClinicalTrials.gov registry record · Phase 1
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01569750 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 33 participants.
The verdict
NCT01569750, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to identify if, and at what dose, ibrutinib may be administered with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and to document responses of this combination in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Interventions
- DRUG Part 1, Cohort 1
- DRUG Part 1, Cohort 2
- DRUG Part 1, Cohort 3
- DRUG Part 2, Cohort 1
- DRUG Part 2, Cohort 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-06-14 |
| Est. Completion | 2014-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01569750
The ClinicalTrials.gov registry entry for NCT01569750 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Part 1, Cohort 1 is the first listed.
NCT01569750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01569750 about?
NCT01569750 is a clinical study titled "A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma". The purpose of this study is to identify if, and at what dose, ibrutinib may be administered with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and to document responses of this combination in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
What is the current status of trial NCT01569750?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2012-06-14. Estimated completion is 2014-09-04.
What interventions are being tested in trial NCT01569750?
The interventions under investigation include: Part 1, Cohort 1 (DRUG), Part 1, Cohort 2 (DRUG), Part 1, Cohort 3 (DRUG), Part 2, Cohort 1 (DRUG), Part 2, Cohort 2 (DRUG).
Who is sponsoring clinical trial NCT01569750?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.